5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Immunological features of patients affected by Barraquer-Simons syndrome

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          C3 hypocomplementemia and the presence of C3 nephritic factor (C3NeF), an autoantibody causing complement system over-activation, are common features among most patients affected by Barraquer-Simons syndrome (BSS), an acquired form of partial lipodystrophy. Moreover, BSS is frequently associated with autoimmune diseases. However, the relationship between complement system dysregulation and BSS remains to be fully elucidated. The aim of this study was to provide a comprehensive immunological analysis of the complement system status, autoantibody signatures and HLA profile in BSS. Thirteen subjects with BSS were recruited for the study. The circulating levels of complement components, C3, C4, Factor B (FB) and Properdin (P), as well as an extended autoantibody profile including autoantibodies targeting complement components and regulators were assessed in serum. Additionally, HLA genotyping was carried out using DNA extracted from peripheral blood mononuclear cells.

          Results

          C3, C4 and FB levels were significantly reduced in patients with BSS as compared with healthy subjects. C3NeF was the most frequently found autoantibody (69.2% of cases), followed by anti-C3 (38.5%), and anti-P and anti-FB (30.8% each). Clinical data showed high prevalence of autoimmune diseases (38.5%), the majority of patients (61.5%) being positive for at least one of the autoantibodies tested. The HLA allele DRB1*11 was present in 54% of BSS patients, and the majority of them (31%) were positive for *11:03 (vs 1.3% in the general population).

          Conclusions

          Our results confirmed the association between BSS, autoimmunity and C3 hypocomplementemia. Moreover, the finding of autoantibodies targeting complement system proteins points to complement dysregulation as a central pathological event in the development of BSS.

          Related collections

          Most cited references45

          • Record: found
          • Abstract: found
          • Article: not found

          C3 glomerulopathy — understanding a rare complement-driven renal disease

          The C3 glomerulopathies are a group of rare kidney diseases characterized by complement dysregulation occurring in the fluid phase and in the glomerular microenvironment, which results in prominent complement C3 deposition in kidney biopsy samples. The two major subgroups of C3 glomerulopathy — dense deposit disease (DDD) and C3 glomerulonephritis (C3GN) — have overlapping clinical and pathological features suggestive of a disease continuum. Dysregulation of the complement alternative pathway is fundamental to the manifestations of C3 glomerulopathy, although terminal pathway dysregulation is also common. Disease is driven by acquired factors in most patients, namely autoantibodies that target the C3 or C5 convertases. These autoantibodies drive complement dysregulation by increasing the half-life of these vital but normally short-lived enzymes. Genetic variation in complement-related genes is a less frequent cause. No disease-specific treatments are available, although immunosuppressive agents and terminal complement pathway blockers are helpful in some patients. Unfortunately, no treatment is universally effective or curative. In aggregate, the limited data on renal transplantation point to a high risk of disease recurrence (both DDD and C3GN) in allograft recipients. Clinical trials are underway to test the efficacy of several first-generation drugs that target the alternative complement pathway.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Human adipsin is identical to complement factor D and is expressed at high levels in adipose tissue.

            A cDNA for human adipsin was isolated and shown to encode a protein sharing 98% amino acid sequence similarity with the protein sequence previously determined for purified natural human complement factor D. Like mouse adipsin, recombinant human adipsin displays the enzymatic activity of human complement factor D, cleaving complement factor B only when B is complexed with activated complement component C3. We conclude that human adipsin is equivalent to complement factor D and that adipsin is the homologue of factor D in rodents. Adipose tissue is a major site of synthesis of human adipsin/complement factor D mRNA, but unlike the case in rodents, human adipsin mRNA is also expressed in monocytes/macrophages. The data presented here, demonstrating the equivalence of human adipsin to complement factor D and its high level of expression in fat, suggest a previously unsuspected role for adipose tissue in immune system biology.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Lipodystrophy Syndromes.

              Lipodystrophies are heterogeneous disorders characterized by varying degrees of body fat loss and predisposition to insulin resistance and its metabolic complications. They are subclassified depending on degree of fat loss and whether the disorder is genetic or acquired. The two most common genetic varieties include congenital generalized lipodystrophy and familial partial lipodystrophy; the two most common acquired varieties include acquired generalized lipodystrophy and acquired partial lipodystrophy. Highly active antiretroviral therapy-induced lipodystrophy in patients infected with human immunodeficiency virus and drug-induced localized lipodystrophy are common subtypes. The metabolic abnormalities associated with lipodystrophy include insulin resistance, hypertriglyceridemia, and hepatic steatosis. Management focuses on preventing and treating metabolic complications.
                Bookmark

                Author and article information

                Contributors
                fcorvillo@yahoo.es
                Journal
                Orphanet J Rare Dis
                Orphanet J Rare Dis
                Orphanet Journal of Rare Diseases
                BioMed Central (London )
                1750-1172
                10 January 2020
                10 January 2020
                2020
                : 15
                : 9
                Affiliations
                [1 ]ISNI 0000 0000 8970 9163, GRID grid.81821.32, Complement Research Group, Hospital La Paz Institute for Health Research (IdiPAZ), , La Paz University Hospital, ; Paseo de la Castellana, 261, 28046 Madrid, Spain
                [2 ]ISNI 0000 0004 1791 1185, GRID grid.452372.5, Center for Biomedical Network Research on Rare Diseases (CIBERER U754), ; Madrid, Spain
                [3 ]ISNI 0000 0004 1756 8209, GRID grid.144189.1, Obesity and Lipodystrophy Centre at the Endocrinology Unit, , University Hospital of Pisa, ; Pisa, Italy
                [4 ]ISNI 0000 0000 8970 9163, GRID grid.81821.32, Unit of Immunology, , La Paz University Hospital, ; Madrid, Spain
                [5 ]Immunogenetics and Histocompatibility, Instituto de Investigación Sanitaria Puerta de Hierro, Madrid, Spain
                [6 ]ISNI 0000 0004 1756 8209, GRID grid.144189.1, Immunogenetics laboratory, , University Hospital of Pisa, ; Pisa, Italy
                [7 ]ISNI 0000000109410645, GRID grid.11794.3a, Thyroid and Metabolic Diseases Unit (U.E.T.eM.), Centro Singular de Investigación en Medicina Molecular e Enfermidades Crónicas (CIMUS-IDIS), School of Medicine, , Universidad de Santiago de Compostela, ; Santiago de Compostela, Spain
                [8 ]ISNI 0000000119578126, GRID grid.5515.4, Universidad Autónoma de Madrid, ; Madrid, Spain
                Author information
                http://orcid.org/0000-0001-6418-5647
                Article
                1292
                10.1186/s13023-019-1292-1
                6954565
                31924231
                0ee01784-e6c8-40e0-9c95-95e105655e50
                © The Author(s). 2020

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 12 September 2019
                : 29 December 2019
                Funding
                Funded by: FundRef http://dx.doi.org/10.13039/501100010198, Ministerio de Economía, Industria y Competitividad, Gobierno de España;
                Award ID: PI15-00255
                Award ID: PI08-1449
                Award Recipient :
                Funded by: Comunidad de Madrid (ES)
                Award ID: B2017/BMD3673
                Award Recipient :
                Funded by: Asociación Española de Familiares y Afectados de Lipodistrofias
                Funded by: FundRef http://dx.doi.org/10.13039/501100010801, Xunta de Galicia;
                Award ID: ED341b 2017/19
                Award Recipient :
                Categories
                Research
                Custom metadata
                © The Author(s) 2020

                Infectious disease & Microbiology
                complement system,lipodystrophy,barraquer-simons syndrome,c3 nephritic factor,autoimmunity,acquired partial lipodystrophy

                Comments

                Comment on this article